Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

The effect of antigen dose on T cell-targeting vaccine outcome.

Billeskov R, Beikzadeh B, Berzofsky JA.

Hum Vaccin Immunother. 2019;15(2):407-411. doi: 10.1080/21645515.2018.1527496. Epub 2018 Oct 25.

PMID:
30277831
2.

High Antigen Dose Is Detrimental to Post-Exposure Vaccine Protection against Tuberculosis.

Billeskov R, Lindenstrøm T, Woodworth J, Vilaplana C, Cardona PJ, Cassidy JP, Mortensen R, Agger EM, Andersen P.

Front Immunol. 2018 Jan 15;8:1973. doi: 10.3389/fimmu.2017.01973. eCollection 2017.

3.

Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity.

Frey BF, Jiang J, Sui Y, Boyd LF, Yu B, Tatsuno G, Billeskov R, Solaymani-Mohammadi S, Berman PW, Margulies DH, Berzofsky JA.

J Immunol. 2018 Mar 1;200(5):1853-1864. doi: 10.4049/jimmunol.1701523. Epub 2018 Jan 26.

4.

Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques.

Sui Y, Frey B, Wang Y, Billeskov R, Kulkarni S, McKinnon K, Rourke T, Fritts L, Miller CJ, Berzofsky JA.

PLoS Pathog. 2017 May 12;13(5):e1006395. doi: 10.1371/journal.ppat.1006395. eCollection 2017 May.

5.

Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy.

Billeskov R, Wang Y, Solaymani-Mohammadi S, Frey B, Kulkarni S, Andersen P, Agger EM, Sui Y, Berzofsky JA.

J Immunol. 2017 May 1;198(9):3494-3506. doi: 10.4049/jimmunol.1600965. Epub 2017 Mar 27.

6.

Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis.

Billeskov R, Tan EV, Cang M, Abalos RM, Burgos J, Pedersen BV, Christensen D, Agger EM, Andersen P.

PLoS One. 2016 Aug 15;11(8):e0161217. doi: 10.1371/journal.pone.0161217. eCollection 2016.

7.

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.

Knudsen NP, Olsen A, Buonsanti C, Follmann F, Zhang Y, Coler RN, Fox CB, Meinke A, D'Oro U, Casini D, Bonci A, Billeskov R, De Gregorio E, Rappuoli R, Harandi AM, Andersen P, Agger EM.

Sci Rep. 2016 Jan 21;6:19570. doi: 10.1038/srep19570.

8.

Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules.

Solaymani-Mohammadi S, Lakhdari O, Minev I, Shenouda S, Frey BF, Billeskov R, Singer SM, Berzofsky JA, Eckmann L, Kagnoff MF.

J Leukoc Biol. 2016 Mar;99(3):475-82. doi: 10.1189/jlb.4A0115-003RR. Epub 2015 Oct 14.

PMID:
26467188
9.

Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model.

Billeskov R, Christensen JP, Aagaard C, Andersen P, Dietrich J.

PLoS One. 2013 Aug 19;8(8):e72185. doi: 10.1371/journal.pone.0072185. eCollection 2013.

10.

The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity.

Billeskov R, Elvang TT, Andersen PL, Dietrich J.

PLoS One. 2012;7(6):e39909. doi: 10.1371/journal.pone.0039909. Epub 2012 Jun 29.

11.

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P.

Nat Med. 2011 Feb;17(2):189-94. doi: 10.1038/nm.2285. Epub 2011 Jan 23.

PMID:
21258338
12.

Difference in TB10.4 T-cell epitope recognition following immunization with recombinant TB10.4, BCG or infection with Mycobacterium tuberculosis.

Billeskov R, Grandal MV, Poulsen C, Christensen JP, Winther N, Vingsbo-Lundberg C, Hoang TT, van Deurs B, Song YH, Aagaard C, Andersen P, Dietrich J.

Eur J Immunol. 2010 May;40(5):1342-54. doi: 10.1002/eji.200939830. Erratum in: Eur J Immunol. 2011 Mar;41(3):873.

13.

Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose.

Aagaard C, Hoang TT, Izzo A, Billeskov R, Troudt J, Arnett K, Keyser A, Elvang T, Andersen P, Dietrich J.

PLoS One. 2009 Jun 16;4(6):e5930. doi: 10.1371/journal.pone.0005930.

14.

Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis.

Hoang TT, Nansen A, Roy S, Billeskov R, Aagaard C, Elvang T, Dietrich J, Andersen P.

PLoS One. 2009 Jun 16;4(6):e5928. doi: 10.1371/journal.pone.0005928.

15.

CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.

Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh Hoang T, Holst P, Thomsen AR, Andersen P, Dietrich J.

PLoS One. 2009;4(4):e5139. doi: 10.1371/journal.pone.0005139. Epub 2009 Apr 9.

16.

Tuberculosis subunit vaccines: from basic science to clinical testing.

Doherty TM, Dietrich J, Billeskov R.

Expert Opin Biol Ther. 2007 Oct;7(10):1539-49. Review.

PMID:
17916046
17.
18.
19.

Hippocampal neuron and glial cell numbers in Parkinson's disease--a stereological study.

Joelving FC, Billeskov R, Christensen JR, West M, Pakkenberg B.

Hippocampus. 2006;16(10):826-33.

PMID:
16941622

Supplemental Content

Loading ...
Support Center